Skip to Main Content

Paper Details

Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance).
Neurooncol Adv
4
2022
Bevacizumab, CD105, Cancer, GBM, Patients, TRC105, anemia, anti-CD105, antibody TRC105, bevacizumab, glioblastoma, patients, recurrent
Author NameAffiliation
Nicholas ButowskiUniversity of California San Francisco
Nicholas ButowskiUniversity of California San Francisco
David SchiffUniversity of Virginia Health System
Susan GeyerMayo Clinic
Priya KumthekarLou and Jean Malnati Brain Tumor Institute
Caterina GianniniMayo Clinic
Caterina GianniniMayo Clinic
Patrick Y WenCenter for Neuro-Oncology
  • 1 - 8

Datasets

Release 1.2